Clinical Trials Browser

Phase 2 × Withdrawn × liposomal doxorubicin × Clear all

NCT05295589 2023-09-26

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Phase 2 Withdrawn

Platinum-Refractory Fallopian Tube Carcinoma

NCT00706953 2015-04-06

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT01281943 2013-07-04

Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer

Phase 2 Withdrawn

Gastrointestinal

Liver Neoplasms

NCT00434031 2012-07-30

CETRA

Phase 2 Withdrawn

Breast Neoplasms

NCT01492881 2012-05-11

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma

NCT00610792 2009-07-14

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Phase 2 Withdrawn

Ovarian Neoplasms